agilon health, inc. (NYSE:AGL) Stake Boosted by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its stake in agilon health, inc. (NYSE:AGL - Free Report) by 326.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,415,419 shares of the company's stock after buying an additional 1,083,492 shares during the period. JPMorgan Chase & Co. owned about 0.34% of agilon health worth $5,563,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in AGL. Virtu Financial LLC acquired a new stake in agilon health during the third quarter valued at approximately $120,000. Geode Capital Management LLC raised its position in shares of agilon health by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 6,893,517 shares of the company's stock valued at $27,097,000 after acquiring an additional 84,889 shares in the last quarter. Barclays PLC lifted its stake in agilon health by 21.2% during the third quarter. Barclays PLC now owns 1,228,952 shares of the company's stock worth $4,830,000 after purchasing an additional 214,830 shares during the last quarter. XTX Topco Ltd boosted its holdings in agilon health by 271.1% in the third quarter. XTX Topco Ltd now owns 119,747 shares of the company's stock worth $471,000 after purchasing an additional 87,481 shares during the period. Finally, State Street Corp increased its stake in agilon health by 3.0% during the third quarter. State Street Corp now owns 7,449,706 shares of the company's stock valued at $29,277,000 after purchasing an additional 215,733 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on AGL shares. Stifel Nicolaus reduced their price target on shares of agilon health from $7.00 to $2.00 and set a "hold" rating on the stock in a research report on Tuesday, November 12th. Barclays decreased their target price on agilon health from $5.00 to $2.00 and set an "underweight" rating for the company in a research note on Monday, November 11th. TD Cowen lowered their target price on agilon health from $6.00 to $2.00 and set a "hold" rating for the company in a report on Monday, November 11th. Sanford C. Bernstein raised their price target on agilon health from $2.50 to $3.15 and gave the stock a "market perform" rating in a report on Wednesday. Finally, William Blair downgraded agilon health from an "outperform" rating to a "market perform" rating in a research note on Friday, November 8th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, agilon health currently has a consensus rating of "Hold" and a consensus target price of $4.03.

agilon health Price Performance

Shares of AGL stock traded up $0.16 during midday trading on Friday, reaching $3.12. 7,729,587 shares of the company were exchanged, compared to its average volume of 5,393,844. The company's 50 day moving average price is $2.07 and its two-hundred day moving average price is $3.67. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.29 and a current ratio of 1.29. The company has a market cap of $1.28 billion, a P/E ratio of -3.31 and a beta of 0.53. agilon health, inc. has a 12 month low of $1.50 and a 12 month high of $7.73.

agilon health (NYSE:AGL - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.19). The firm had revenue of $1.45 billion during the quarter, compared to analyst estimates of $1.47 billion. agilon health had a negative return on equity of 47.84% and a negative net margin of 6.88%. During the same quarter last year, the company earned ($0.06) earnings per share. On average, sell-side analysts expect that agilon health, inc. will post -0.59 earnings per share for the current year.

Insider Activity

In other agilon health news, Director Diana Mckenzie acquired 12,500 shares of the stock in a transaction dated Monday, November 25th. The shares were bought at an average price of $2.28 per share, with a total value of $28,500.00. Following the purchase, the director now directly owns 51,319 shares of the company's stock, valued at approximately $117,007.32. This trade represents a 32.20 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Karen Mcloughlin bought 25,000 shares of the business's stock in a transaction that occurred on Friday, December 13th. The shares were acquired at an average cost of $2.20 per share, with a total value of $55,000.00. Following the completion of the purchase, the director now owns 73,166 shares of the company's stock, valued at approximately $160,965.20. The trade was a 51.90 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 90,000 shares of company stock worth $198,100 over the last 90 days. 3.20% of the stock is currently owned by company insiders.

About agilon health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.